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Abstract
Background: Eczema is common in children and in the UK most cases are managed in primary care. The foundation of
all treatment is the regular use of leave-on emollients to preserve and restore moisture to the skin. This not only improves
comfort but may also reduce the need for rescue treatment for ‘flares’, such as topical corticosteroids. However, clinicians
can prescribe many different types of emollient and there is a paucity of evidence to guide this choice. One reason for
this may be the challenges of conducting a clinical trial: are parents or carers of young children willing to be
randomly allocated an emollient and followed up for a meaningful amount of time?
Design: This is a single-centre feasibility study of a pragmatic, four-arm, single-masked, randomized trial. Children with
eczema who are eligible (from 1 month to less than 5 years of age, not known to be sensitive or allergic to any of study
emollients or their constituents) are recruited via their general practices. Participants are allocated Aveeno® lotion,
Diprobase® cream, Doublebase® gel or Hydromol® ointment via a web-based system, using a simple randomization
process in a 1:1:1:1 fashion. Researchers are masked to the study emollient. Participants are assessed at baseline and
followed up for 3 months. Data are collected by daily diaries, monthly researcher visits and review of electronic medical
records. Because this is a feasibility study, a formal sample size calculation for the estimation of treatment effectiveness
has not be made but we aim to recruit 160 participants.
Discussion: Recruitment is on-going. At the end of the study, as well as being able to answer the question, ‘Is it is
possible to recruit and retain children with eczema from primary care into a four-arm randomized trial of emollients?’,
we will also have collected important data on the acceptability and effectiveness of four commonly used emollients.
Trial registration: Current Controlled Trials ISRCTN21828118 and Clinical Trials Register EudraCT2013-003001-26.
Keywords: children, eczema, emollients, feasibility, primary care, RCT
Background
Childhood eczema is the most common inflammatory
skin disease, affecting around 20% of children in the UK,
with the peak incidence in the first two years of life [1].
Eczema, characterized by dry and itchy skin, can have a
significant impact on the quality of the affected child’s
life and that of the child’s family – the more severe the
eczema, the greater the effect [2]. The resulting impair-
ment in health-related quality of life is comparable to
that of other chronic diseases of childhood, including
diabetes and asthma [3]. Eczema also places a significant
financial burden on both families and the National
Health Service (NHS) [4]. In the UK, the majority of
children with eczema are diagnosed and their treatment
is managed exclusively by their general practitioners
(GPs) [5].
The cornerstone of eczema treatment in all settings is
the regular application of ‘leave-on’ emollients, which
rehydrate and improve the comfort of dry skin [6].
There is also some evidence to suggest that emollients
reduce the need for topical corticosteroids [7], which are
used to treat disease ‘flares’ but which can have harmful
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effects if applied inappropriately. Clinicians in primary
care can prescribe a wide variety of emollients, which
come in different formulations (lotions, creams, gels and
ointments), varying in consistency from ‘light’ to ‘heavy’.
Light preparations (creams and lotions) have a high water
content, are absorbed quickly and are more cosmetically
acceptable but may require more frequent application.
Heavy preparations (ointments) have a longerlasting
effect, owing to their high oil content, but as a conse-
quence make the skin feel greasy.
There is weak and limited research evidence to guide
which emollient should be prescribed and how often it
should be applied [8]. The last systematic review of ec-
zema treatments was published in 2000 and concluded
that there was ‘a virtual absence of clinically useful ran-
domized controlled trials data on the use of emollients
in atopic eczema’ [9], with five published randomized
controlled trials being criticized for poor quality of
reporting, poor analysis or short duration. Subsequently,
the 2007 NICE guidelines on the management of atopic
eczema [10] and the GREAT database (an on-line re-
pository of trials in eczema) [11] have not identified any
significant new studies of emollients in eczema.
It is therefore unsurprising that different clinicians
prescribe different emollients, leading to emollients be-
ing only partly used (or not at all) and multiple consulta-
tions before parents or carers are recommended an
emollient that works for their child. Indeed, some
families may ‘give up’ and turn to less orthodox treat-
ments, which may be harmful [12]. This is important to
the NHS because, in addition to the cost of wasted med-
icines and repeat consultations, it may be that the older,
cheaper emollients are as effective as, or better than,
newer, more expensive ones. Sound data are also required
to support the belief that regular use of emollients reduces
exacerbations of eczema and topical corticosteroid use. It
is an issue of importance to both patients and doctors:
“Which emollients are the most effective and safe in treat-
ing eczema?” emerged as one of the highest priorities for
further research in a recent research priority setting
exercise [13].
Therefore, there is a need for robust randomized trial
evidence with regards to the most clinically and cost-
effective emollients for eczema. However, there are a
number of challenges in undertaking such a study. First,
choosing which emollients should be compared – the
British National Formulary for Children [14] lists over
30 alternatives. Second, establishing the optimal means
of recruiting children into the study and ensuring that
short and medium-term outcome data on effectiveness
and cost can be collected. Third, choosing the most ap-
propriate primary outcome measure. To our knowledge,
no study has attempted to address these key questions
in primary care.
The aim of the Choice of Moisturiser for Eczema
Treatment (COMET) study is to determine whether a
clinical trial comparing four different emollients for the
treatment of childhood eczema can be conducted and to
obtain important information that will inform the design
and size of a definitive trial.
Methods
Design
COMET is a feasibility study of a pragmatic, single-
masked, randomized clinical trial to compare the clinical
benefit and cost-effectiveness of leave-on emollients in
the treatment of children with eczema in primary care.
The aim is to recruit 160 children, randomly allocate
them to one of four emollients and follow them up for 3
months. The primary means of data collection are
parent-completed daily diaries, monthly assessments,
and retrospective review of electronic medical records.
Setting
General practices located in Bristol, South Gloucester-
shire and North Somerset will be invited to participate
in the trial via the West of England Clinical Research
Network.. We aim to recruit practices from a diversity of
settings, using different computer systems and with
varying levels of research activity and experience. Cri-
teria for entry into the trial include having at least one
GP trained in good clinical practice and a willingness to
undertake patient mail-outs and prescribe the study
emollients.
Participants
Children are eligible if they: are aged from 1 month to
under 5 years; have eczema (diagnosed by a doctor or an
appropriately qualified health care professional with
oversight from a medically qualified doctor); and are not
known to be sensitive or allergic to any of the study
emollients or their constituents. An adult with parental
responsibility must consent for the child to participate.
Throughout this paper, the term ‘parent’ will be used to
denote all carers or guardians.
Eligibility will be confirmed by an appropriately qualified
health care professional for patients referred by the prac-
tice, with oversight from a medically qualified doctor, or
by the chief investigator (or his deputy) for patients who
self-refer. All those making eligibility decisions will be
trained in good clinical practice.
Recruitment
There are two recruitment methods: ‘self-referral’ or ‘in
consultation’.
‘Self-referral’ is defined as when parents of potentially
eligible children are invited to contact the research team
directly by means of a practice mailshot, practice waiting
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room posters or study flyers. Parents who respond have
their child’s eligibility and understanding of the study
checked by a researcher. Once confirmed, written in-
formed consent is received at the baseline visit.
‘In consultation’ is defined as when parents of eligible
children are recruited by a GP or practice nurse during a
surgery visit (which need not be for the child’s eczema).
The GP or practice nurse establishes eligibility, receives
written informed consent and conducts the randomization.
Practice nurses and GPs are asked to record all approaches
to potentially eligible participants in a recruitment log.
Intervention and assignment of intervention
Participants are randomly allocated to one of four emol-
lients (Aveeno® lotion 400 ml, Diprobase® cream 500 g,
Doublebase® gel 500 g, Hydromol® ointment 500g) to use
as their primary leave-on emollient with directions to
‘Use twice daily and when required.’ These were chosen
because they represent each of the different formulations
(lotion, cream, gel and ointment), are among the most
commonly prescribed and vary in cost. In addition, Dou-
blebase® and Diprobase® emerged as the most popular in
a patient preference study and mechanistic studies have
shown that these emollients enhance skin barrier func-
tion (Professor Hywel Williams, personal communica-
tion). Allocation is done by the Bristol Randomised
Trials Collaboration web-based system, using a simple
randomization process in a 1:1:1:1 allocation.
All study emollients are prescribed for the duration of
the study by the participant’s GP surgery as per normal
care. For children recruited via the self-referral route,
randomization is conducted by the trial coordinator (or
the trial coordinator’s deputy) upon confirmation of eli-
gibility and consent, who will then contact the practice
to arrange prescription of the study emollient. For chil-
dren recruited in consultation, the recruiting GP or
practice nurse is responsible for randomization and pre-
scribes the allocated emollient at that visit. This process
is kept secret from the researchers who perform the
assessment visits.
Therefore COMET is a single-masked study, where
clinician, parent and trial coordinator are unmasked but
the researchers undertaking the baseline and follow-up
visits are masked. This is to ensure that the ‘objective’
assessments of eczema severity are unbiased, that is are
not influenced by researcher knowledge of the type of
emollient being used. To maintain masking, the follow-
ing steps will be taken. First, researchers undertaking the
assessments do not have access to the randomization
system and are not able to identify which emollient has
been assigned to which participant. Second, clinicians
and parents are asked not to disclose which treatment
they are using. Third, to minimize the risk of unmasking
due to differences between emollients when applied to
the skin (their look, feel or smell), parents are asked to
maximize the amount of time between application and
the assessment visits. Fourth, parents are also asked to
ensure that the emollient container is hidden from view.
Researcher masking will be assessed using the Bang
blinding index [15], which takes a value between −1 and
+1: +1 indicates complete lack of masking and 0 is con-
sistent with perfect masking. Negative values indicate
that the respondent is wrong more often than would be
expected by chance, which can arise, for example, if all
participants are said to be on one particular treatment
irrespective of what they receive. The index can be pre-
sented with confidence intervals and can be used as the
basis of a test of the null hypothesis that the respondent
is randomly guessing each participant’s allocation.
Routine clinical care is not affected – children will at-
tend appointments for their eczema as normal and use
other medications (for example, topical corticosteroids)
as normally directed. If, during the course of the study,
children have a reaction to the study emollient or par-
ents wish to change for another reason, the clinicians in
charge are free to prescribe any alternative as per their
normal clinical practice. Co-prescribing of other leave-
on emollients and bath additives will be discouraged, but
allowed.
Outcome measures
Participants will be followed up monthly (every 28 days)
for 3 months (total 84 days). As this is a feasibility study,
the primary outcome is the proportion of children
approached who were randomized to a study emollient
and used it for the duration.
Secondary outcome measures relate to the feasibility
of the study:
 Data completeness of daily, weekly and monthly
measures, recorded by parents and collected by
research assistants.
 The extent to which the research assistants were
kept masked to intervention.
 Preliminary data on the clinical effectiveness of the
proposed study emollients, including the quantity
and frequency of emollient application, and evidence
of any effect on topical corticosteroid or calcineurin
inhibitor use.
 Qualitative feedback from parents of participants
regarding the logistics and acceptability of trial
processes, procedures and paperwork.
Data collection
How, when and by whom the data are collected are
summarized in Table 1.
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Parent-completed daily diary
At enrolment, parents are given the option of complet-
ing a paper or electronic (app) version of the diary; and
the option of automatic text reminders to encourage
completion. They are asked to record use of emollient
and topical corticosteroid or calcineurin inhibitor on a
daily basis; detail contacts with healthcare professionals,
eczema-related costs and the Patient-Orientated Eczema
Measure [16] weekly; and complete Dermatitis Family
Impact [17], Quality of Life [18] and global assessment
questionnaires monthly.
Assessment visits
At the baseline visit, the researcher collects sociodemo-
graphic information, data on eczema diagnosis and treat-
ments used, and asks the parents to complete the
Dermatitis Family Impact questionnaire. At baseline and
monthly follow-up visits, researchers undertake objective
assessments of eczema severity (Eczema Area Severity
Index; [19] Six Area, Six Sign Atopic Dermatitis severity
score; [20] Three Item Severity score [21]) and measure-
ments of skin hydration at the antecubital fossa and
forearm (three measurements in each area) using a cor-
neometer (Corneometer® CM825, Courage & Khazaka
electronic GmbH, Cologne, Germany). Standardized
procedures written in accordance with guidelines on bio-
physical skin measurements are followed [22].
At the final visit, parents are asked to complete an exit
questionnaire. Parents who choose to withdraw from the
study at any point are asked to complete a withdrawal
questionnaire.
Review of electronic medical record
The primary care electronic medical records of consented
children are reviewed for the 3 months they are in the
study. Data on relevant prescriptions (emollients, topical
and oral corticosteroids, topical calcineurin inhibitors) and
health care use (number of consultations with GP or
practice nurse and of dermatology out-patient attendances)
are extracted.
Data management
Parents of all participating children will be asked to provide
consent using paper consent forms (Additional file 1).
Consent forms and study questionnaires (case report
forms) will be stored securely and made accessible only to
the research team and authorized personnel.
Data from case report forms completed on paper by
the participant or research team are entered in a study
database, which incorporates data validation rules to
reduce data entry errors, and management functions to
facilitate auditing and data quality assurance. A random
sample of 10% of diary and visit case report forms will
be checked, by the trial research team, against entries in
the database for quality purposes. At the end of the trial,
the database will be cleaned and locked.
Patient identifiers will be kept in a separate system
from the clinical data. The database and randomization
Table 1 Type, timing and means of data collected about participants in COMET study
Data collected Frequency and timing of data collection
Baseline Months 1–3 End of study
Daily Weekly Monthly
Medical history R
Eczema Area and Severity Index R
Six Area, Six Sign Atopic Dermatitis severity score R
Three Item Severity score R
Skin corneometry R
Study emollient use P
Other emollient or bath additive use P
Topical corticosteroid or calcineurin inhibitor use P
Patient-Orientated Eczema Measure GP, PN or R P
Health care consultation attendance P
Eczema-related costs (out-of-pocket expenditure by parent) P
Time off work and nursery or day care due to eczema P
Dermatitis Family Impact R P
Patient Global Assessment R P
Quality of life R P
Review of electronic medical record GP or PN
GP, general practitioner; P, parent-completed daily diary; PN, practice nurse; R, research team member
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system will be designed to protect patient information, in
line with the UK Data Protection Act (1998). The research
team will ensure that participants’ anonymity is main-
tained through secure handling and storage of patient in-
formation at the trial centre. Participants will be identified
only by a patient ID number on the case report form.
Analysis
Participant recruitment and follow-up via each of the
two recruitment pathways will be reported using a
CONSORT flowchart showing the numbers of people
approached, eligible, recruited and randomized (with
reasons for exclusions).
The proportion of children approached who were
randomized to a study emollient and used it for the
duration of the study (the primary outcome measure)
will be reported. We will explore how participant
recruitment and retention varies by recruitment pathway
and practice and participant characteristics.
We will report data completeness of daily, weekly and
monthly measures, recorded by parents and collected by
the research team. In respect of the diary, we will com-
pare data completeness between paper, with or without
text reminders, and app versions. We will also, by refer-
ring to participants’ electronic medical record data, assess
accuracy and completeness of parent-recorded diary data.
The different outcome measures will be presented as
summary statistics, to allow sensitivity of each measure
to change over time to be compared. The different
emollients will be compared in terms of these summary
outcome measures, and in terms of parent-completed
questionnaires, to identify any early evidence of the in-
feriority of a particular emollient, which would inform
the choice of emollients to be included in the main trial.
Feedback from parents of participants regarding satis-
faction with the allocated emollient and trial processes,
procedures and paperwork will be presented. Bang blind-
ing index data will be presented to evaluate the success of
keeping researchers masked to treatment allocation.
We will test the feasibility of using data collected dur-
ing the trial to carry out a cost-effectiveness study from
the perspectives of the NHS, parents, and the value of
lost productivity. Data on resource use collected via the
patient diary will be used to identify the level of missing-
ness, by item, and which items are important cost
drivers. This information will be used in designing data
collection for the economic evaluation in the full trial.
NICE recommends the use of quality-adjusted life years
as the preferred outcome measure in economic evalua-
tions. However, no validated generic measure of health-
related quality of life is psychometrically and conceptu-
ally robust enough for young children under the age of
3. We are therefore using a preference-based measure of
health in children with atopic dermatitis [18] in this
feasibility study, which will indicate the value of using it
to estimate quality-adjusted life years in the full trial.
Sample size
Because this is a feasibility study, a formal sample size
calculation for the estimation of treatment effectiveness
has not be made. We will aim for a target sample size of
160, 40 in each arm. With this number, a true consent rate
of 50% (160 children participating having invited 320 po-
tentially eligible children) will be estimated, with a 95%
confidence interval of the order 44% to 56%. This is suffi-
ciently precise to inform the design of a definitive trial.
Monitoring
The University of Bristol will act as sponsor for the trial
(reference UoB2009). Because of the low risk nature of
the study, it is being overseen by a joint Trial Steering
and Data Monitoring Committee (TS/DM-C). The over-
all role of the TS/DM-C, which is independent of the
sponsor, is to safeguard the interests of the trial’s partici-
pants, potential participants, investigators and sponsor;
and to monitor the trial’s overall conduct, and protect its
validity and credibility. No formal interim statistical ana-
lyses are planned: it is expected that the study recruit-
ment will terminate when the intended sample size have
been achieved. The committee will be masked to the
identity of the treatment arms unless unexpected num-
bers of adverse events warrant examination of data by
treatment allocation.
All adverse events will be recorded in participants’
study diaries. Expected adverse reactions to study emol-
lients (for example, pruritus or erythema) will be col-
lated and reviewed at Trial Management Group and TS/
DM-C meetings. Expected non-serious (for example, upper
respiratory tract viral infections, diarrhoea or vomiting)
and serious (for example, lower respiratory tract infections
or urinary tract infections) adverse events that cannot be
causally related to study participation will not be reported.
Expected serious adverse events that might be related to
study participation will be reported to the sponsor within
24 hours of knowledge of the event. All relevant infor-
mation about a suspected unexpected serious adverse
reaction will be reported within 7 days to the Medicines
and Healthcare Products Regulatory Agency (MHRA)
and the ethics committee.
The chief investigator and study sites will allow moni-
tors, persons responsible for the audit, representatives of
the ethics committee and of the regulatory authorities to
have direct access to source data and documents. Trial
monitoring will be undertaken on behalf of the Sponsor
by University Hospitals Bristol NHS Foundation Trust
following their standard monitoring procedures.
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Ethics
The study was approved by the Central Bristol Research
Ethics Committee (reference: 13/SW/0297), clinical trial
authorization was given by the MHRA (reference: 03299/
0017/001-003) and research governance approvals were
obtained across all areas prior to recruitment. The study
will be conducted in accordance with the principles of
good clinical practice, UK Research Governance Frame-
work and the Medicines for Human Use (Clinical Trial)
Regulations 2006.
The current protocol version is 1.3. Version 1.0 (October
2013) was the version submitted for research ethics
committee approval. Version 1.1 (November 2013) was
the version first approved by both the research ethics
committee and MHRA. Version 1.2 (May 2013) included
minor wording and timeline changes and amendments to
descriptions of study procedures, including adverse event
reporting. Version 1.3 (November 2014) included revised
eligibility criteria (from ‘child aged between 1 month and
3 years with doctor-diagnosed eczema’ to ‘child aged be-
tween 1 month and 5 years of age with eczema (diagnosed
by a doctor or an appropriately qualified health care pro-
fessional with oversight from a medically qualified doc-
tor)’) and recruitment of additional sites. All amendments
have been approved by the relevant regulatory bodies and
communicated to relevant parties.
Dissemination
Following a separate agreed publication policy, we will
disseminate findings through local and national net-
works, including key professional, public stakeholder
and educational organizations. Dissemination will also
occur via oral presentations and posters to national pri-
mary care and dermatological scientific conferences, and
by publication in peer-reviewed journals. For promo-
tional and informative purposes, the study website [23]
and on-line social media (Twitter [24] and Facebook
[25]) are publically accessible. A summary of the main
findings will be distributed via these routes at the end of
the study and specifically for the participants involved.
Discussion
This is the first study to determine the feasibility of a
large trial to answer the research question, ‘What is the
most clinically and cost-effective primary emollient to
prescribe for young children with eczema?’ A feasibility
study is necessary because there are a number of key
uncertainties, including: optimal means of patient recruit-
ment; the choice of interventions; feasibility of long-term
patient-reported data collection; and the avoidance of
bias in outcome measurement when parents cannot be
kept masked from their children’s allocated treatments.
In addition to establishing the feasibility of the definitive
study, we are collecting data around the acceptability
and effectiveness of four commonly used emollients,
which may guide the choice of emollients in any future
study.
During the first 7 months of recruitment, children had
to be between 1 month and 3 years of age and have their
eczema diagnosis confirmed by a doctor. Because of
concerns about recruitment, we obtained permission to
revise the eligibility criteria for the last 5 months of re-
cruitment to: ‘Child aged between 1 month and 5 years
of age with eczema (diagnosed by a doctor or an appro-
priately qualified health care professional with oversight
from a medically qualified doctor)’.
Since the study was originally proposed, the HOME
initiative has published welcome guidance on which
measures of clinical signs should be included as a core
outcome in clinical trials of patients with eczema (Ec-
zema Area Severity Index) [26]. When the study was de-
signed, there was uncertainty about which of the more
commonly used means of assessing eczema severity
should be used, hence the inclusion of three (Eczema
Area Severity Index, Six Area, Six Sign Atopic Derma-
titis severity score, Three Item Severity score) outcomes.
However, it was always our intention to use this ‘dupli-
cation’ of effort to undertake secondary, methodological
work, comparing the different measures and any rela-
tionship with the data on skin hydration we will obtain
using the corneometer.
Despite this being a feasibility study of four of the
emollients most commonly prescribed in the UK, which
are also available to buy over the counter, COMET has
been classed as a controlled trial of an investigational
medicinal product in children. The associated regulation
and accompanying paperwork and approval required
have increased the set-up time and made study manage-
ment more complex. Set-up was further complicated by
the anomaly that in the UK two of the emollients are
classed as medicines (Diprobase® cream and Doublebase®
gel), one as a cosmetic product (Aveeno® lotion) and
another as a medical device (Hydromol® ointment).
All participants are allocated an emollient (that is,
there is no control group) because we believed that clini-
cians and parents would be reluctant to take part in a
study where they might not be prescribed anything spe-
cifically to moisturize the skin; and because it would
probably be deemed unethical to do so. It is possible
that, depending on the acceptability and preliminary
effectiveness findings, the number of emollients in the
main trial could be reduced. It is not possible to mask
carers and clinicians because the study emollients are
very different in their consistency and smell, and because
we are asking GP surgeries to prescribe the treatment.
At the end of the study, we will have established the
feasibility of the main trial and produced valuable prelim-
inary data on emollient acceptability and effectiveness. In
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the definitive trial, we will be able to compare the clinical
and cost-effectiveness of the study emollients and in sec-
ondary analyses will be able to examine, for example, for
evidence of a ‘steroid-sparing’ effect of emollients. As a
consequence the treatment of children with eczema
should be improved and costs to the NHS and patients re-
duced through fewer consultations and more efficient
prescribing.
Trial status
Recruitment started June 2014 and finished 30 April 2015.
Additional file
Additional file 1: Participant consent form.
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